Back to Journals » Journal of Inflammation Research » Volume 18

Myofibrillogenesis Regulator-1 in Smooth Muscle Cells Modulates Inflammation Signaling Pathways via Regulating ROCK1 Ubiquitination and Degradation to Impact Aortic Dissection [Corrigendum]

Authors Yin H, Li X, Lu D, Zhao X, Yang Z, Wang Z, Xu F, Chen Y, Li C

Received 9 June 2025

Accepted for publication 9 June 2025

Published 18 July 2025 Volume 2025:18 Pages 9557—9558

DOI https://doi.org/10.2147/JIR.S545659



Yin H, Li X, Lu D, et al. J Inflamm Res. 2025;18:1719–1738.

The authors have advised there are clerical errors on pages 1720, 1721 and 1729 of the published paper. Specifically:

Page 1720, line 4, the text “The intima, characterized” should read “The media, characterized”.

Page 1721, Materials and Methods, Human Aortic Collection section, line 7, the text “confirmed by coronary CTA. Non-clamped aortic” should read “confirmed by aortic CTA. Non-AD aortic”.

Page 1729, Figure 3 legend, line 5, the text “n=3” should read “NF-kappaB p65 phosphorylation activation was based on four independent experiments (n=4); all other data in this panel were based on n=3”.

The authors have also advised the sentence “The duplication occurred in Figures 3A, 3C and 5C (β-actin) because the experimental conditions and sample sources for these groups were consistent” was missed from the legend of Figure 5 on page 1732. The correct legend and Figure 5 are as follows.

Figure 5 MR-1 Affects AD Progression by Regulating the ROCK1-NF-kappaB p65 Signaling Pathway. (A and B) Co-localization of MR-1 (green) with ROCK1 (red) in human vSMCs induced by angiotensinII for 24 hours. Scale bar= 50 μm. (C and D) Protein immunoblotting and quantitative analysis of ROCK1 upon inhibition of MR-1 and (E and F) protein immunoblotting and quantitative analysis of MR-1 upon inhibition of ROCK1 in human vSMCs induced by angiotensinII for 24 hours (one-way ANOVA followed by Bonferroni post hoc test). β-actin was used as a loading control. n=3. (G) RT-PCR was performed to detect mRNA levels of ROCK1 in human vSMCs treated with angiotensinII in the presence or absence of MR-1 siRNA (one-way ANOVA followed by Bonferroni post hoc test). n=3. Data are shown as mean ± SEM. All data are based on biological replicates. The duplication occurred in Figures 3A, 3C and 5C (β-actin) because the experimental conditions and sample sources for these groups were consistent. *P < 0.05, **P < 0.01, ***P < 0.001.

The authors apologize for these errors.


Read the original article


Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.